# Viatris Inc (VTRS) — capital_return/buyback_authorization [pending]
Source: SEC API (secapi.ai) · situation sit_ee8f0f44ae9fba818883 · retrieved 2026-08-12T06:59:33.769Z

## Overview
Viatris Inc. is a global healthcare company with a broad portfolio spanning generics, value-added medicines, established brands, and innovative medicines that address areas of significant unmet need.

Viatris Inc. signed a definitive agreement in August 2026 to sell the global product rights for Tyrvaya® to Harrow, Inc., a leading provider of ophthalmic disease management solutions in North America. The transaction includes an upfront payment of $30 million and an additional $70 million in commercial contingent milestone payments. The sale reflects Viatris's continued focus on prioritizing its capital, talent, and resources toward opportunities it believes offer the greatest long-term growth potential.

## Terms
- Counterparty: Harrow, Inc. · Deal value: $100.0M · Consideration: cash

## Key dates
- Announced 2026-08-06

## Timeline
- 2026-08-06 · 8-K (0001792044-26-000037): 8-K - Viatris Inc — *Viatris Inc. is a global healthcare company with a broad portfolio spanning generics, value-added medicines, established brands, and innovative medicines that address areas of significant unmet need.* Viatris Inc. signed a definitive agreement in August 2026 to sell the global product rights for Tyrvaya® to Harrow, Inc., a leading provider of ophthalmic disease management solutions in North America. The transaction includes an upfront payment of $30 million and an additional $70 million in commercial contingent milestone payments. The sale reflects Viatris's continued focus on prioritizing its capital, talent, and resources toward opportunities it believes offer the greatest long-term growth potential.
  https://www.sec.gov/Archives/edgar/data/1792044/0001792044-26-000037.txt

## Citations
- 0001792044-26-000037 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000179204426000037